# Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

> **NCT03894748** · PHASE2,PHASE3 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 168 (actual)

## Conditions studied

- Glabella Line Severity

## Interventions

- **DRUG:** Botulinum Toxin Type A

## Key facts

- **NCT ID:** NCT03894748
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-08
- **Final completion:** 2012-10
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03894748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03894748, "Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03894748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*